A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

This study is testing a new antibody-drug treatment called CHT101 that targets a protein called CD70 on cancer cells, in people with certain relapsed or refractory blood cancers — including T-cell lymphoma, B-cell lymphoma, and chronic lymphocytic leukemia. **You may be eligible if...** - You are between 18 and 70 years old - Your tumor tissue has tested positive for CD70 by laboratory testing - You have a specific type of blood cancer (T-cell lymphoma, B-cell lymphoma, or CLL) that has come back or stopped responding to standard treatments - You have received the minimum number of prior treatment regimens required for your cancer type - You are in generally good physical condition **You may NOT be eligible if...** - Cancer has spread to your brain or spinal cord - You have had an organ transplant - You have previously received CAR-T therapy or CD70-targeting drugs - You have an active infection requiring treatment - You have an active autoimmune disease requiring immunosuppressive medication Talk to your doctor to see if this trial is right for you.